Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | HSD11B1 | P28845 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23251841 | 0.90 | SMN1; SMN2 (0.50) | SMN1; SMN2HSD11B1KDM4EGAA | |
| SCHEMBL25075221 | 0.90 | SMN1; SMN2 (0.50) | SMN1; SMN2HSD11B1KDM4EEPHX1EPHX2 | |
| SCHEMBL25075072 | 0.82 | SMN1; SMN2 (0.41) | SMN1; SMN2 | |
| SCHEMBL26455978 | 0.82 | SMN1; SMN2 (0.41) | SMN1; SMN2KDM4EALDH1A1GAA | |
| SCHEMBL19267939 | 0.79 | GNAI3 (0.48) | SMN1; SMN2 | |
| SCHEMBL18117392 | 0.79 | SMN1; SMN2 (0.38) | SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL26452614 | 0.79 | SMN1; SMN2 (0.46) | SMN1; SMN2KDM4EALDH1A1GAA | |
| SCHEMBL25075073 | 0.79 | KCNH2 (0.40) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL19130734 | 0.79 | KCNH2 (0.56) | — | |
| SCHEMBL19130714 | 0.79 | KCNH2 (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022081928-A1 | TRICYCLIC HETEROBIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF TARGETED PROTEINS | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20200361944-A1 | FRAGMENT SYNTHESIS OF CYCLIC PEPTIDES | ZEALAND PHARMA A/S (DK) | 2020-11-19 | — | — | US | disclosed |
| US-20160220637-A1 | Pharmaceutical Compositions of Growth Hormone Secretagogue Receptor Ligands | IPSEN PHARMA S.A.S. (FR) | 2016-08-04 | — | — | US | disclosed |
| US-20110118278-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160220637-A1 | Pharmaceutical Compositions of Growth Hormone Secretagogue Receptor Ligands | GHSR, GHRHR, SSTR5 | SMN1; SMN2 3597/4885HSD11B1 1254/4885KDM4E 3946/4885 |
| US-20200361944-A1 | FRAGMENT SYNTHESIS OF CYCLIC PEPTIDES | VIP, NPPA, NGLY1 | SMN1; SMN2 3377/4885HSD11B1 1479/4885KDM4E 4748/4885 |
| US-20110118278-A1 | CARBAMOYL DERIVATIVES OF BICYCLIC CARBONYLAMINO-PYRAZOLES AS PRODRUGS | DMPK, DCK, MAP3K19 | SMN1; SMN2 4039/4885HSD11B1 3602/4885KDM4E 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.